Pharming (PHAR) Non-Current Debt (2019 - 2022)
Pharming's (PHAR) quarterly Non-Current Debt came in at $143000.0 in Q3 2022, down 62.95% YoY from $386000.0 in Q3 2021, and down 5.92% on a QoQ basis from $152000.0 in Q2 2022.
Pharming (PHAR) Non-Current Debt (2019 - 2022) Analysis & Trends
Pharming (PHAR) has 4 years of Non-Current Debt data on file, last reported at $143000.0 in Q3 2022.
- Quarterly Non-Current Debt fell 62.95% year-over-year to $143000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $143000.0 (down 62.95% YoY) and the FY2021 annual result came in at $165000.0, down 22.17% from the prior year.
- Non-Current Debt slipped to $143000.0 in Q3 2022, from $152000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $19.1 million in Q4 2019 to a low of $143000.0 in Q3 2022.
- A 4-year average of $2.3 million and a median of $189000.0 in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2020 — Non-Current Debt plunged 98.92% — and 2022, when it retreated 14.29%.
- Tracing PHAR's Non-Current Debt over 4 years: stood at $19.1 million in 2019, then sank by 98.92% to $206266.1 in 2020, then dropped by 19.58% to $165875.8 in 2021, then retreated by 13.79% to $143000.0 in 2022.
- The last three Non-Current Debt figures came in at $143000.0 (Q3 2022), $152000.0 (Q2 2022), and $162000.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 143,000.00 |
| Jun 30, 2022 | 152,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 165,875.79 |
| Sep 30, 2021 | 386,000.00 |
| Jun 30, 2021 | 189,000.00 |
| Mar 31, 2021 | 189,000.00 |
| Dec 31, 2020 | 206,266.14 |
| Dec 31, 2019 | 19.13 Mn |